Skip to main content

Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses.

Publication ,  Journal Article
Huang, Y; Alam, S; Andersen-Nissen, E; Carpp, LN; Dintwe, OB; Flach, BS; Grunenberg, N; Laher, F; De Rosa, SC; Ferrari, G; Innes, C; Gray, GE ...
Published in: Viruses
August 27, 2024

Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An exploratory objective of the HVTN 097 phase 1b trial was to assess whether immune responses [focusing on those supported as correlates of risk (CoR) of HIV acquisition] induced via the RV144 pox-prime HIV vaccine regimen correlated with those induced via tetanus toxoid (TT) and/or hepatitis B virus (HBV) vaccines. We measured TT-specific and HBV-specific IgG-binding antibody responses and TT-specific and HBV-specific CD4+ T-cell responses at multiple time points in HVTN 097 participants, and we assessed their correlations at peak time points with HIV vaccine (ALVAC-HIV and AIDSVAX B/E)-induced responses. Four correlations were significant [false discovery rate-adjusted p-value (FDR) ≤ 0.2]. Three of these four were with IgG-binding antibody responses to TT measured one month after TT receipt, with the strongest and most significant correlation [rho = 0.368 (95% CI: 0.096, 0.588; p = 0.008; FDR = 0.137)] being with IgG-binding antibody responses to MN gp120 gDneg (B protein boost) measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. The fourth significant correlation [(rho = 0.361; 95% CI: 0.049, 0.609; p = 0.021; FDR = 0.137)] was between CD4+ T-cell responses to a hepatitis B surface antigen peptide pool, measured 2 weeks after the third HBV vaccination, and IgG-binding antibody responses to gp70BCaseAV1V2 (B V1V2 immune correlate), measured two weeks after the second ALVAC-HIV and AIDSVAX B/E boost. These moderate correlations imply that either vaccine, TT or HBV, could potentially provide a moderately useful immunogenicity predictor for the ALVAC-HIV and AIDSVAX B/E HIV vaccine regimen.

Duke Scholars

Published In

Viruses

DOI

EISSN

1999-4915

Publication Date

August 27, 2024

Volume

16

Issue

9

Location

Switzerland

Related Subject Headings

  • Young Adult
  • Viral Vaccines
  • Tetanus Toxoid
  • Male
  • Immunoglobulin G
  • Immunogenicity, Vaccine
  • Humans
  • Hepatitis B Vaccines
  • HIV-1
  • HIV Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Huang, Y., Alam, S., Andersen-Nissen, E., Carpp, L. N., Dintwe, O. B., Flach, B. S., … Gilbert, P. B. (2024). Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses. Viruses, 16(9). https://doi.org/10.3390/v16091365
Huang, Ying, Shomoita Alam, Erica Andersen-Nissen, Lindsay N. Carpp, One B. Dintwe, Britta S. Flach, Nicole Grunenberg, et al. “Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses.Viruses 16, no. 9 (August 27, 2024). https://doi.org/10.3390/v16091365.
Huang Y, Alam S, Andersen-Nissen E, Carpp LN, Dintwe OB, Flach BS, et al. Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses. Viruses. 2024 Aug 27;16(9).
Huang Y, Alam S, Andersen-Nissen E, Carpp LN, Dintwe OB, Flach BS, Grunenberg N, Laher F, De Rosa SC, Ferrari G, Innes C, Bekker L-G, Kublin JG, McElrath MJ, Tomaras GD, Gray GE, Gilbert PB. Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses. Viruses. 2024 Aug 27;16(9).

Published In

Viruses

DOI

EISSN

1999-4915

Publication Date

August 27, 2024

Volume

16

Issue

9

Location

Switzerland

Related Subject Headings

  • Young Adult
  • Viral Vaccines
  • Tetanus Toxoid
  • Male
  • Immunoglobulin G
  • Immunogenicity, Vaccine
  • Humans
  • Hepatitis B Vaccines
  • HIV-1
  • HIV Infections